RECOVERY & TISSUE REPAIR / MATRIX
Singles vs. Blends: TB-500, GLOW and KLOW Side by Side
How one well-studied single ingredient compares to the two popular multi-peptide blends built around it — in mechanism, evidence, and what's actually known about the combinations themselves.
The short version
This page lines up TB-500, GLOW (research blend) and KLOW on the things that matter most when reading Recovery & Tissue Repair peptide research: what each one actually contains, how mature the evidence is, and what's genuinely known versus assumed about combining ingredients.
The short story: TB-500 is a single, well-defined peptide fragment with its own — if still thin — human safety data. GLOW takes that fragment and adds two more repair-oriented peptides for a blend leaning toward skin renewal. KLOW takes GLOW's three ingredients and adds a fourth, anti-inflammatory peptide, leaning harder toward joint and tendon recovery. All three share one important fact: none of the combinations has ever been tested as a combination in a controlled study. Every blend claim on this site is a mechanistic sum of its separately-studied parts, and this page says so plainly rather than implying otherwise.
The comparison matrix
| Dimension | TB-500 | GLOW (research blend) | KLOW |
|---|---|---|---|
| What it is | A single 7-amino-acid fragment of thymosin beta-4 | 3-peptide blend: GHK-Cu + BPC-157 + TB-500 | 4-peptide blend: KPV + GHK-Cu + BPC-157 + TB-500 |
| Main framing | Cell migration / tissue repair | Skin renewal + tissue repair | Broader recovery + anti-inflammatory |
| Human evidence for its parts | Full-length protein: 1 Phase 1 RCT, n=40 [13]; the fragment itself: minimal | GHK-Cu: clinical/topical reviews [4][5]; BPC-157: 3 small pilots [2] | Adds KPV: gut-cell + mouse data only [8]; BPC-157 IV pilot, n=2 [6] |
| Combination tested as a whole? | Not applicable — single ingredient | No controlled study of the 3-peptide blend | No controlled study of the 4-peptide blend |
| Regulatory / anti-doping status | WADA-prohibited (thymosin beta-4 category) [1] | Contains TB-500 — WADA-prohibited by inclusion [1][13] | Contains TB-500 — WADA-prohibited by inclusion [1][13] |
| Key caution | Human safety of the fragment specifically is largely unstudied [1][13] | Untested combination; copper load from GHK-Cu [1][4] | Untested 4-way combination; mismatched clearance rates [13] |
What each one actually contains
TB-500 is the simplest case: one peptide, one sequence (Ac-LKKTETQ), the actin-binding fragment of thymosin beta-4. GLOW adds two more ingredients to that single peptide — GHK-Cu, a copper-carrying tripeptide, and BPC-157, a 15-amino-acid gut-derived peptide — in a commonly listed ratio around 50 mg GHK-Cu to 10 mg each of BPC-157 and TB-500. KLOW takes that exact three-peptide starting point and adds a fourth ingredient, KPV, a three-amino-acid anti-inflammatory peptide, typically also at 10 mg, bringing the usual vial to about 80 mg total. None of these ratios is pharmacopeial or independently standardized — they vary between suppliers.
How mature is the evidence?
Evidence maturity varies a lot across these three entries, and it's worth being honest about where each one actually sits. For TB-500, the fragment itself has essentially no completed human trials; the strongest human data — a well-tolerated Phase 1 study up to 1,260 mg — used the full-length parent protein, not the small piece sold commercially [13]. GLOW's ingredients individually range from fairly solid (GHK-Cu's topical and cosmetic literature) to thin (BPC-157's three small human pilots) [2][4]. KLOW adds a fourth ingredient, KPV, whose human evidence is essentially absent — the strongest data are gut-cell experiments and a mouse colitis model [8] — plus a small two-person BPC-157 intravenous safety pilot [6]. Across all three entries, the pattern repeats: individual-ingredient research exists at varying strength, but combination-level research does not exist at all. No study anywhere has tested GLOW or KLOW as formulated blends against their separate ingredients or against placebo.
Regulatory and anti-doping status
All three entries carry the same regulatory reality because they all include TB-500: thymosin beta-4, the protein TB-500 is fragmented from, is named on the World Anti-Doping Agency's Prohibited List and banned at all times, in and out of competition [1]. That means TB-500 alone, GLOW, and KLOW are all off-limits for tested athletes, regardless of how the product is marketed. None of the three has any FDA-approved therapeutic indication — all are supplied strictly as research chemicals for laboratory use, not for human consumption. GHK-Cu, present in GLOW and KLOW, is the one component with a legal cosmetic-ingredient status in its topical Copper Tripeptide-1 form, but that status does not extend to injectable, systemic use within a blend.
Key caution for each
For TB-500, the defining caution is that the small fragment's human safety is genuinely unstudied — the reassuring Phase 1 numbers exist for the full-length protein, not the piece actually sold [1][13]. For GLOW, the defining caution is the combination itself: three peptides with very different clearance rates, mixed in one vial, with no combined safety data and a copper load from GHK-Cu that people with copper-handling conditions should weigh carefully [1][4]. For KLOW, the same untested-combination caution applies to a fourth ingredient, and the mismatched pharmacokinetics are even more pronounced across four different molecules rather than three [13]. Read together, the throughline is simple: more ingredients means more individually-studied mechanisms, but not more combination-level evidence.